Last reviewed · How we verify
NCT06226610
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Phase 2 trial testing Dupilumab in Pruritis in 46 participants. Currently enrolling.
31 January 2026
Quick facts
| Lead sponsor | Akron Children's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 21 November 2024 |
| Primary completion | 31 January 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dupilumab (DUPILUMAB) — full drug profile →
- Placebo
Conditions studied
- Pruritis — all drugs for Pruritis →
Sponsor
Akron Children's Hospital
Who can join
Adults 18 to 60, any sex, with Pruritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Promising Strategies for the Management of Burn-Wound-Associated Pruritus.
Tenenhaus M, Rennekampff HO. · · 2025 · PMID 39982335 · DOI 10.3390/ebj6010002
Verify or expand the search:
- PubMed search for NCT06226610
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dupilumab
Trials testing the same drug.
- NCT07316114 — A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spont · recruiting
- NCT07277322 — Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases · Phase 1, PHASE2 · not yet recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07399067 — A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
Other Akron Children's Hospital trials
Trials by the same sponsor.
- NCT07221630 — Conventional Ultrafiltration Versus Dilutional Ultrafiltration in Pediatric CPB Patients · not yet recruiting
- NCT05627531 — Meaning Making While Your Child is in Intensive Care · NA · completed
- NCT03053401 — Ultrasound Guided Adductor Canal Versus Femoral Nerve Blocks for Anterior Cruciate Ligament Reconstruction in Pediatrics · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06226610 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akron Children's Hospital
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06226610.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing